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Abstract
Drug use is prevalent throughout prison populations, and, despite advances in drug treatment programmes for
inmates, access to and the quality of these programmes remain substantially poorer than those available for non-
incarcerated drug users. Because prisoners may be at greater risk for some of the harms associated with drug use,
they deserve therapeutic modalities and attitudes that are at least equal to those available for drug users outside
prison. This article discusses drug use by inmates and its associated harms. In addition, this article provides a survey
of studies conducted in prisons of opioid substitution therapy (OST), a clinically effective and cost-effective drug
treatment strategy. The findings from this overview indicate why treatment efforts for drug users in prison are
often poorer than those available for drug users in the non-prison community and demonstrate how the imple-
mentation of OST programmes benefits not only prisoners but also prison staff and the community at large. Finally,
the article outlines strategies that have been found effective for implementing OST in prisons and offers sugges-
tions for applying these strategies more broadly.
Introduction: Drug use by prisoners
Drug use remains endemic among incarcerated popula-
tions [1,2]. In Europe, the prevalence of drug depen-
dence among prisoners varies from country to country;
a systematic review of the literature found the preva-
lence to range from 10% to 48% for male prisoners and
30% to 60% for female prisoners at the point of incar-
ceration [3]. In the United States, the number of people
incarcerated annually for drug-related offenses in the
past 20 years has grown from 40,000 to 450,000, leading
to prison populations with high rates of drug use [4].
Imprisonment of drug users for crimes they commit–
often to support their addiction–contributes to prison-
ers’ high prevalence of drug dependence [5]. A lifetime
history of incarceration is common among intravenous
drug users (IDUs); 56% to 90% of IDUs have been
imprisoned previously [6]. Drug-using prisoners may be
continuing a habit acquired before incarceration or may
acquire the habit in prison [7,8]. In Europe, 16% to 60%
of prisoners who injected outside prison continued to
inject while incarcerated [5], whereas 7% to 24% of pris-
oners who injected said they started in prison [5]. In
another study, one-fifth of prisoners injected drugs for
the first time in prison [9].
Imprisonment also favours high-risk behaviour regard-
ing drugs because of concentrated at-risk populations
and risk-conducive conditions such as overcrowding and
violence. The consequences of drug use in prison
include drug-related deaths, suicide attempts and self-
harm. Drug use tends to be more dangerous inside than
outside prisons because of the scarcity of drugs and
sterile injecting equipment [5,10,11]. In a study of 492
IDUs, 70.5% reported sharing needles while in prison
compared with 45.7% who shared needles in the month
before imprisonment (P < 0.0001) [9]. Of particular con-
cern is that sharing injecting equipment inside prisons is
a primary risk factor for human immunodeficiency virus
transmission [12]. Additionally, hepatitis C virus infec-
tion through shared injecting equipment in prison has
been reported in studies undertaken in Australia [13,14]
and Germany [15]. Drug use in prison is also associated
with the risk for involvement in violence. Inmates who
incur disciplinary action related to possession or use of
a controlled substance or contraband were 4.9 times
more likely to display violent or disruptive behaviour
than those who did not incur such disciplinary action
[16]. Prisoners using drugs are also at risk for engaging
in further illicit activity [17]. If discovered using illegal
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security rules and eliciting hostility among prison staff
[2,12].
Unless a prisoner receives adequate treatment, drug
addiction and dependence and their attendant dangers
persist after the prisoner’s release into the community
and are associated with a high rate of overdose and
other harms. Overall, the determining factor in drug-
related deaths soon after release appears to be altered
tolerance to opioids [18]. In the week after release, pris-
oners are approximately 40 times more likely to die
than are members of the general population; in this
immediate post-release period, more than 90% of deaths
are drug related [18]. Among women, the odds of a
drug-related death in the first week after release were >
10 times greater than at 52 weeks (overall risk [OR] =
10.6; 95% confidence interval [CI] = 4.8-22.0); among
men, the odds were ~8 times greater (OR = 8.3; 95% CI
= 5.0-13.3) [19]. Very high rates of drug-related mortal-
ity persist at least through the first 2 weeks after release
from prison [20]. Among the costs to society for an
inmate’s failure to fully reform while in prison is
increased risk for recidivism. Within 12 months of
release from prison, 58% of heroin users who did not
receive opioid substitution therapy (OST) were re-incar-
cerated compared with 41% of those who did receive
OST [21].
This article provides a non-systematic overview of the
literature comparing the quality of drug treatment for
inmates with their non-incarcerated counterparts. Gui-
dance regarding the implementation of drug treatment
programmes was collected from the literature and
included herein. All searches were conducted using
Web-based search engines (e.g. PubMed, EMBASE) or
abstract archiving system (e.g. SciFinder) combining
terms related to incarceration (eg, prison, prisoner) with
terms related to drug misuse and treatment (eg, heroin,
OST); the end date for searches was December 2009.
Current state of drug treatment health care
efforts for inmates
Many data attest to the low quality or non-existence of
drug treatment health care ef f o r t sf o rp r i s o n e r sc o m -
pared with efforts made for non-prisoner drug users.
For example, in early 2007, 24 of 25 European Union
member states had needle exchange programmes in the
community, but only three had such programmes in
prisons, and only Spain covered all prisons [7]. An inter-
national survey reported in 2009 that at least 37 coun-
tries offered OST in community settings but not in
prison settings [22]. European countries not offering
OST in prison include Bulgaria, Cyprus, Estonia, Greece,
Latvia, Lithuania, Slovakia and Sweden [22]. OST was
considered any treatment for opioid dependence using a
medicinal opioid such as methadone, buprenorphine or
buprenorphine/naloxone [22]; this differs from metha-
done maintenance treatment (MMT), in which metha-
done is the only agent used for substitution therapy.
Universally, the percentage of drug users offered OST
varied considerably from prison to prison (from 2% to
16.2%), but utilisation of these programmes was uni-
formly low (e.g. 7.8% of drug addicts in French prisons
received OST) [23]. In most European countries that
offered OST in prison, access to and varieties of avail-
able OST programmes were heterogeneous and incon-
sistent [5,24]. For example, although OST is nominally
available in German prisons, implementation is the
responsibility of each of the 16 federal states and often
varies from prison to prison within states [25]. In
France, many physicians have been reluctant to initiate
OST in prison or even to renew existing buprenorphine
or methadone prescriptions for prisoners [26]. If substi-
tution treatment is provided, it is often limited to drug
detoxification [5,17]. Furthermore, most efforts to scale
up OST in the community have not been carried
through to the prison setting [24,27,28].
Why is drug treatment for prisoners not yet
comparable to that available for non-incarcerated
drug users?
Several factors affect the extent to which prisons provide
OST, including the varied health policies of prisons and
the difficulties in employing adequate numbers and
quality of prison staff [26]. Some prisoners are pre-
vented from entering an OST programme because of
excessively restrictive criteria [22]. For example, in some
countries OST is limited to inmates who are serving
sentences of a particular length, were in treatment
before imprisonment or can confirm that they are
enrolled in a post-release treatment programme [22]. In
Croatia, OST is restricted to persons aged 25 and older
who used illegal drugs for ≥ 10 years and heroin for ≥ 5
years [29]. Other limitations related to OST in prisons
include a deficiency of psychological and social support
for drug-using prisoners [5] and lack of or limited
access to certain OST programmes, such as buprenor-
phine-based regimens, that may be more suitable for
use in prison [27,30].
Several theoretical and functional reasons have
resulted in drug treatment for prisoners not having par-
ity with drug users in the community. In particular,
some societal misconceptions pervade the medical man-
agement of drug dependence. There exists a poor
understanding of opioid dependence as a chronic and
recurring disease; some clinicians may feel that a hedo-
nistic practice indicates a weakness of character [5,24].
Another widespread but mistaken belief involves the
benefits of abstinence for drug users, which leads to the
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which in turn leads to reversion to opioid use [31]. In
Her Majesty’s Prison at Leeds, 43% of prisoners with an
illicit opioid habit continued to acquire and use opioids
even through the first days of imprisonment and com-
pletion of a detoxification regimen [32]. There are also
socioeconomic reasons drug-using prisoners, particularly
IDUs, do not receive appropriate therapy for their drug
problem: they are frequently poor and deprived and,
therefore, marginalised [33] and not considered worthy
of treatment. These beliefs delay the implementation of
OST, as does the common perception that prisons
should be “drug-free zones” [5]. Prison authorities may
also be concerned that OST undermines their efforts to
reduce the drug supply in their institutions (i.e. a black
market for drugs) [5,33] and that providing needles is,
in effect, placing “weapons” in inmates’ hands [26].
Rationales for drug dependence treatment in
prisons
Benefits for the prisoner
There are many reasons drug-using prisoners should be
afforded the same quality of health care regarding drug
maintenance treatment–including OST–as is available
to non-prisoners [12,34,35]. Primarily, it is appropriate
to treat prisoners’ drug use so that they will not leave
prison in worse health than when they entered [33].
OST is recognised as one of the most effective treat-
ment options for opioid dependence [34]. It can
decrease the high cost of opioid dependence to users,
their families and society at large by reducing heroin
use, associated deaths, HIV-risk behaviours and criminal
activity. Substitution maintenance therapy is established
as a critical component of community-based approaches
in the management of opioid dependence.
Many studies have demonstrated the successful appli-
cation of OST in prison populations with regard to pris-
oner-centred and non-prisoner-centred outcomes.
Positive prisoner-centred outcomes associated with OST
include reduced rates of drug abuse and infectious dis-
eases. Prisoners receiving MMT have shown less drug-
injecting [11,36,37] and less risk-taking behaviour (e.g.
sharing of syringes) [11,38]. In one study, only 1 of 18
(5.6%) prisoners receiving MMT reported heroin use in
the past 30 days compared with 15 of 40 (37.5%) prison-
ers not receiving MMT (P < 0.05) [36]. After 4 months
in prison, the rate of illicit use of morphine was 27% for
MMT-treated prisoners and 42% for controls (P =0 . 0 5 )
[39]. The use of buprenorphine maintenance therapy in
prisons has been based chiefly on results obtained
outside prisons [23,25]; however, there is growing
experience with buprenorphine in prisons [29]. A group
of prisoners receiving buprenorphine reported for
their designated post-release treatment programme
significantly more often than did a comparison group
receiving methadone (48% vs. 14%, respectively; P <
0.001) [40]. A 2-year study in Puerto Rico is under way
to examine the feasibility of initiating prisoners with his-
tories of heroin addiction on buprenorphine/naloxone
before their release to determine the effectiveness of
such treatment with regard to post-release treatment
entry, reduction in heroin use and reduction in criminal
activity at 1 month after release [41].
OST in prison has also been associated with reduced
rates of infectious disease. Adequate OST has been asso-
ciated with reduced risk for HCV infection [39], whereas
inadequate MMT–p e r i o d so f<5m o n t h si no n es t u d y ,
for example–was found to be significantly associated
with increased risk for HCV seroconversion (P = 0.01)
[42]. Prisoners receiving MMT with a daily dose > 60
mg during their whole prison sentence were found to be
least likely to inject heroin, share needles and engage in
HIV risk-taking behaviour while in prison [38]. In
another study, needle-sharing and drug-injecting beha-
viour decreased significantly among prisoners receiving
MMT for > 6 months [43]. Additionally, in Spain, there
was a significantly reduced sharing of needles by IDUs
in an OST programme (Marco A, 1995, personal com-
munication). OST has also been associated with a
reduced risk for prisoner death. In one study, no deaths
were recorded while prisoners were enrolled in MMT,
whereas 17 prisoners died while not enrolled in MMT,
representing an untreated mortality rate of 2.0 per 100
person-years (95% CI, 1.2-3.2) [42]. Finally, prisoners
receiving MMT have shown a decrease in serious vio-
lent drug charges over time, whereas those not receiving
MMT showed an increase [21].
Other positive prisoner-centred outcomes related to
OST in prison can be observed after the term of incar-
ceration is completed. Reduced drug use after release
was reported among prisoners engaged in an MMT plan
[35]. The mean number of days in community-based
drug abuse treatment 1 year post-release–as a function
of in-prison treatment for drug abuse–was 23.1 days’
counselling only in prison; 91.3 days’ counselling plus
passive transfer to treatment upon release; and 166.0
days’ counselling plus methadone treatment in prison
and continued post-release (each pairwise comparison, P
< 0.01). Participants in the counselling-plus-methadone
group were significantly less likely than those in the
other groups to have opioid-positive or cocaine-positive
urine drug test results [44]. OST also lessens the likeli-
hood of released prisoners committing crimes [35]. The
reported number of days of criminal activity in the past
365 days after release was 106.7 (standard deviation
[SD] = 128.7) with counselling only; 65.2 (SD = 96.2)
counselling plus transfer to methadone; and 81.8 (SD =
109.5) days counselling plus methadone [44]. Reduced
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some type of OST [45]. Prisoners on a 12-month MMT
while incarcerated had a lower level of re-incarceration
than heroin-using prisoners with no treatment [21].
Reduced rates of re-incarceration during a 3 1/2-year
period following a first incarceration were related to
maintenance OST in prison [46]. A Correctional Service
of Canada study found that, after 1 year, 41% of
addicted inmates receiving MMT were re-admitted to
prison compared with 58% of addicted inmates who
were not receiving the treatment [46]. Compared with
periods of no MMT in prison, the risk for re-incarcera-
tion was reduced by 70% during MMT periods ≥ 8
months (P < 0.001) [42].
Benefits for the prison staff and community
A major rationale for the use of OST in prison is the
cost-effectiveness of such a strategy. For example, prison
methadone is no more costly than community metha-
done and provides the benefit of reduced heroin use in
prisons with the associated reductions in morbidity and
mortality [47]. The cost of an institutional OST pro-
gramme may be offset by the cost savings accruing from
offenders successfully remaining in the community
longer than equivalent offenders not receiving OST
[21,47]. Expanded access to MMT has an incremental
cost-effectiveness ratio of < $11,000 per quality-adjusted
life-year, which is more cost-effective than many widely
used medical therapies [48]. Implementing OST in pris-
ons is also associated with improvement in inmate man-
ageability and prison safety; total institutional charges
for prisoners enrolled in MMT are lower than for pris-
oners not enrolled in MMT [21]. Reduced drug use and
reduced recidivism were reported among prisoners
engaged in methadone treatment [35].
Strategies for implementing appropriate
maintenance therapy in prisons
Among the more successful strategies for implementing
appropriate maintenance therapy in prisons are those
used in Spain and the United Kingdom. The mechanics
of these programmes may be applicable in other coun-
tries that want to implement appropriate maintenance
programmes in prisons.
The Spain model
For more than 10 years, all prisons in Spain have had a
legal duty to implement MMT programmes involving
syringe exchanges. Incoming prisoners are given a full
medical examination, and those who are drug users are
offered a treatment programme in which medications
are given daily. The laboratory-produced methadone is
pre-packaged with the dose for each prisoner in the pro-
gramme. Prisoners must present identification at the
point of medication dispensing and are watched to
ensure that the complete dose is taken [49].
The United Kingdom model
In the United Kingdom, the prison programme (Inte-
grated Drug Treatment System [IDTS]) is funded to
provide OST in every adult prison, within an integrated
clinical and psychosocial treatment approach, uniting
prisons’ psychosocial drug treatment services (counsel-
ling, assessment, referral, advice and through-care ser-
vices) and clinical substance misuse management
(incorporating the option of MMT or detoxification)
services. The design of the programme took into
account the vulnerability of drug-using prisoners to sui-
cide and self-harm in prison and to death upon release
from prison because of accidental opioid overdose,
prison regimen services that correspond to national and
international good practice and the need to provide clin-
ical interventions that harmonise with practice in the
community and other criminal justice settings.
The United Kingdom programme organised five “work
streams” to develop national policies and strategies that
would (1) facilitate the integration of the two halves of
IDTS; (2) develop a guidance document indicating how
I D T Sw o u l dw o r kw i t hc o m m u n i t ya n dc r i m i n a lj u s t i c e
partners; (3) design and commission a large research
study of IDTS; (4) develop a workforce strategy, setting
out the knowledge and skills requirements for staff
involved in IDTS; and (5) produce a performance man-
agement framework, setting out how indicators of per-
formance would be collated.
Training was planned to ensure that staff responsible
for the well-being or treatment of IDTS service users had
the requisite knowledge and skills for the role. Funding
for the United Kingdom programme included a sufficient
amount for the purchase and installation in prisons of
computer-controlled methadone-dispensing devices.
IDTS partners received guidance on staff recruitment,
with materials for a national advertising campaign. The
creation of shared locations in prisons for IDTS team
members and the provision of adequate space for IDTS
facilities, including harm minimisation groups and treat-
ment rooms, were actively encouraged. From 2008 to
2009, more than 19,000 MMT treatments were adminis-
tered in United Kingdom prisons; this number will con-
tinue to increase until the full implementation of the
IDTS programme occurs in 2010 to 2011.
Guidance on overcoming barriers to the
implementation of substitution programmes in
prisons
Overcoming barriers from the prisoner
Prisoner resistance to participation in a maintenance
programme is often based on a lack of desire to be
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a study of opioid detoxification, 36% declined to be
recruited [32]. A similar lack of desire to be treated may
be seen with regard to OST. Some prisoners may resist
participating in a programme because they do not want
their partners or relatives to know they have been using
drugs. Some may resist treatment with methadone
because they consider methadone a street drug.
Prisoners’ refusal to participate in a maintenance pro-
gramme is best addressed by improving prisoner educa-
tion. Prisoners may be convinced to participate in a
substitution maintenance programme through discus-
sion that includes an explanation and demonstration,
through the use of data, of benefits accruing from in-
prison OST, including easier incarceration with less
desire to inject an illicit drug [17] and the potential for
less violence [16], less risk for prolonging incarceration
or of irritating prison staff [2], less risk for acquiring an
infectious disease [5] and less risk for self-harm. Other
benefits that may be demonstrated are realised after
release from prison, including less desire to commit
crime and, consequently, lower risk for re-incarceration
and lower risks for violence, potentially lethal overdose
[18] and infectious disease [44].
Overcoming barriers from the prison staff and other
stakeholders
Stakeholders who lack understanding or misunderstand
the value of maintenance treatment in prisons–and who
may block the implementation of a treatment pro-
gramme–include politicians, ministerial representatives
and prison staff and professionals. A necessary step in
convincing stakeholders to support the development of
an OST programme is to educate them on the nature of
the opioid drug problem among prisoners and on evi-
dence-based benefits of successful OST, including health
economics benefits.
Stakeholders need instruction that opioid dependence
is a chronically relapsing disease [24] and that coercive
abstinence in prison may be followed by relapse imme-
diately after release, often resulting in overdose, drug
emergencies and death [19]. This education may include
evidence of beneficial results of OST, including reduced
rates of drug abuse, both in prison and after release
from prison [23,25,35,36,39], less risk-taking behaviour
[11,38], reduced rate of infectious disease acquisition
[39,42], reduced risk for death [42], decrease in serious
violent drug charges [21], reduced criminal activity after
release [44] and reduced re-incarceration rate
[21,42,45,46]. Outcomes and health economic data
demonstrating results of studies showing the cost-effec-
tiveness of drug maintenance therapy in prisons [21,47]
should be included. Techniques and resources to gain
support for instituting an OST programme and to
disseminate information in support of such a pro-
gramme include initiating and maintaining contact with
decision-making politicians, the media, the professional
public and non-governmental organisations such as
human rights agencies, the United Nations Office on
Drugs and Crime and the World Health Organization
Regional Office for Europe Health in Prison Project.
Other techniques for obtaining and building support for
a programme include publishing and making available
information on best OST practices; promoting the
exchange of knowledge and experience among scientists,
politicians and practitioners through international and
national conferences of experts from various fields; and
organising local and regional discussions among inter-
ested physicians. Finally, identifying local “champions”
who can knowledgeably explain models of best practice
to their peers and provide opportunities for personnel
who are interested in starting an OST programme to
visit prisons where successful harm reduction pro-
grammes are in operation can be invaluable in the
process.
Stakeholders should be informed that an OST pro-
gramme must provide for the supply of OST medica-
tions. Lack of access to these medications is often a
barrier to the successful implementation of an OST pro-
gramme. Prisons may have a limited list of medications
available for dispensing, and OST maintenance medica-
tions may not be among those available. In some cases,
there may not be medication available to continue main-
tenance therapy that was started before imprisonment.
Prisoners usually do not have health insurance while in
prison and thus cannot afford medication they could
afford outside prison; they are dependent for their medi-
cations on a prison’s health care system.
Prison staffs often express a concern that an OST pro-
gramme introduces the potential risk for internal diver-
sion of maintenance drugs [17]. In some studies, such
diversion was suspected [40], whereas in others it was
found not to be a problem [36]. When diversion was
suspected, it was because of actions such as movement
of a prisoner’s hand to the face when sublingual bupre-
norphine was administered [40]. Because it takes 5 to 10
minutes for a buprenorphine tablet applied sublingually
to be absorbed completely, there is time for it to be
removed from the mouth after insertion for subsequent
potential black-market sale. Prison personnel are often
unwilling to spend the time necessary to observe each
administered dose of buprenorphine in order to prevent
its extraction from the mouth and diversion. Thus,
instead of buprenorphine tablets, prisons are increas-
ingly administering tablets combining buprenorphine
and naloxone to reduce potential diversion and misuse:
applied sublingually, the naloxone is poorly absorbed
and has limited pharmacological effect, whereas the
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sence of naloxone. If a buprenorphine/naloxone tablet is
crushed and used intravenous l y ,t h en a l o x o n ei sb i o a -
vailable; it will counteract the potential euphoric effect
of the buprenorphine and can precipitate severe opioid
withdrawal, a strong deterrent to intravenous misuse of
diverted buprenorphine/naloxone [28].
Finally, lack of adequate funding to cover start-up
costs of a prison OST programme constitutes a barrier
to implementing a programme. To remove this barrier,
the following items must be covered in a programme’s
start-up budget: general administration and administra-
tion of the OST programme; medical and nursing staffs
to execute maintenance therapy assessments, adminis-
tration and delivery; pharmacy and courier services for
stocking, preparation and delivery of medications; dispo-
sable materials used in medicating prisoners; mainte-
nance medication; and correction officers to supervise
medication administration to prisoners [47].
Conclusion
Imprisoned IDUs have the basic right to receive treat-
ment for their drug addiction comparable to treatment
available to IDUs in the community. This treatment
should include OST, a treatment modality with demon-
strated broad benefits to prisoners, both while they are
incarcerated and after their release from prison, as well
as benefits to the community. Examples of successfully
implemented OST programmes exist, and these point to
effective strategies and tactics for establishing OST pro-
grammes elsewhere.
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